Anderl Jan, Faulstich Heinz, Hechler Torsten, Kulke Michael
Heidelberg Pharma GmbH, Ladenburg, Germany.
Methods Mol Biol. 2013;1045:51-70. doi: 10.1007/978-1-62703-541-5_4.
Toxin payloads, or drugs, are the crucial components of therapeutic antibody-drug conjugates (ADCs). This review will give an introduction on the requirements that make a toxic compound suitable to be used in an antitumoral ADC and will summarize the structural and mechanistic features of four drug families that yielded promising results in preclinical and clinical studies.
毒素负载物或药物是治疗性抗体药物偶联物（ADC）的关键组成部分。本综述将介绍使有毒化合物适用于抗肿瘤ADC的要求，并总结在临床前和临床研究中取得有前景结果的四个药物家族的结构和作用机制特点。
